Back
ESC Premium Access

Novel thromboelastography point-of-care test detects all commercially available DOACs at therapeutic concentrations and classifies them as direct thrombin or factor Xa inhibitors with high consistency

Session: Bleeding risk and oral anticoagulation
Topic: Anticoagulants
Speaker: Doctor H. Achneck (Braintree, US)
Event: ESC Congress 2018

Congress Presentation

About the speaker

Doctor Hardean Achneck

Haemonetics Corporation, Braintree (United States of America)
0 follower

3 more presentations in this session

Balancing bleeding risk and effectiveness in patients requiring oral anticoagulation - State of the art

Speaker: Professor P. Kirchhof (Hamburg, DE)

Access
Slides
Video
Thumbnail

Predicting bleeding events in anticoagulated patients with atrial fibrillation: a comparison between HAS-BLED and GARFIELD-AF bleeding score

Speaker: Doctor M. Proietti (Milan, IT)

Access
Abstract
Slides
Video
Thumbnail

How to best predict bleeding risk: clinical or biological tests?

Speaker: Professor R. Kiss (Budapest, HU)

Access
Slides
Video
Thumbnail

Access the full session

Bleeding risk and oral anticoagulation

Speakers: Doctor H. Achneck, Professor P. Kirchhof, Doctor M. Proietti, Professor R. Kiss
Access
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb